The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
|Videos|March 15, 2011
Dr. Langmuir Discusses Vandetanib Clinical Trials
Author(s)Peter Langmuir, MD
eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.
Advertisement
Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses a phase III double-blind study that investigated the use of vandetanib for 331 patients with unresectable locally advanced or metatastic medullary thyroid cancer.
Advertisement
Related to this article
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The top 5 OncLive TV videos of the week cover insights in endometrial cancer, mCRPC, germ cell tumors, melanoma, and HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5